PEO.F
Exelon Corporation
FrankfurtEUREQUITY
Utilities
DELAYED
Last price
38.86
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
38.86
Day high
38.86
Day low
38.20
Volume
15
Market cap
$40.03B
P/E (TTM)
16.68
52W range
35.94 – 43.61
Trailing performance
Returnvs SPY
1W
-0.89%
+0.5%
1M
-4.44%
-8.2%
3M
-1.78%
-4.9%
6M
-5.23%
-16.3%
YTD
+5.14%
-7.1%
1Y
+1.29%
-18.7%
3Y
+4.70%
-69.5%
5Y
+28.70%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PEO.F open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
722.58K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Mar 31, 26 | RICHO ANNA S. Director |
STOCK | 878 | $43.74K | Direct |
| Mar 31, 26 | DEWALT DAVID G Director |
STOCK | 878 | $43.74K | Direct |
| Mar 31, 26 | BOWERS WILLIAM PAUL Director |
STOCK | 878 | $43.74K | Indirect |
| Mar 31, 26 | JOJO LINDA P Director |
STOCK | 878 | $43.74K | Indirect |
| Mar 31, 26 | CHESHIRE MARJORIE RODGERS Director |
STOCK | 878 | $43.74K | Direct |
| Mar 31, 26 | SEGEDI BRYAN K Director |
STOCK | 878 | $43.74K | Direct |
| Mar 31, 26 | LILLIE CHARISSE R Director |
STOCK | 878 | $43.74K | Direct |
| Feb 2, 26 | BUTLER CALVIN G JR. Chief Executive Officer |
— | 198.15K | — | Direct |
| Feb 2, 26 | INNOCENZO MICHAEL A. Chief Operating Officer |
— | 27.47K | — | Direct |
| Feb 2, 26 | HONORABLE COLETTE D. Officer |
— | 8.65K | — | Direct |
| Feb 2, 26 | JONES JEANNE M Officer |
— | 43.41K | — | Direct |
| Feb 2, 26 | KLECZYNSKI ROBERT A. Officer |
— | 12.29K | — | Direct |
| Dec 31, 25 | RICHO ANNA S. Director |
STOCK | 940 | $41.24K | Indirect |
| Dec 31, 25 | DEWALT DAVID G Director |
STOCK | 940 | $41.24K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOWERS WILLIAM PAUL |
Director | — | Stock Award(Grant) |
BUTLER CALVIN G JR. |
Chief Executive Officer | 267.08K | Conversion of Exercise of derivative security |
CHESHIRE MARJORIE RODGERS |
Director | 25.72K | Stock Award(Grant) |
GLOCKNER DAVID |
Officer | 56.70K | Sale |
INNOCENZO MICHAEL A. |
Chief Operating Officer | 89.64K | Conversion of Exercise of derivative security |
JOJO LINDA P |
Director | — | Stock Award(Grant) |
JONES JEANNE M |
Officer | 60.80K | Conversion of Exercise of derivative security |
KLECZYNSKI ROBERT A. |
Officer | 44.68K | Conversion of Exercise of derivative security |
LILLIE CHARISSE R |
Director | 19.80K | Stock Award(Grant) |
YOUNG JOHN FREDERICK |
Director | 32.29K | Stock Award(Grant) |
Fundamentals
Market cap$40.03B
Enterprise value$90.97B
Revenue (TTM)$25.33B
Gross profit$10.73B
EBITDA$8.35B
Net income$2.78B
EPS (TTM)$2.33
Free cash flow$-2.69B
Total cash$1.81B
Total debt$52.67B
Book value / share$24.84
Shares outstanding1.03B
Float1.03B
Short % of float—
Dividend yield3.80%
Beta (5Y)0.40
Valuation & profitability ratios
Trailing P/E16.68
Forward P/E11.88
PEG ratio2.61
Price / sales—
Price / book1.56
EV / revenue3.59
EV / EBITDA10.89
Gross margin42.36%
Operating margin16.59%
Profit margin10.99%
Return on equity9.71%
Return on assets2.81%
Debt / equity177.36
Current ratio1.09
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $24.26B | $23.03B | $21.73B | $19.08B | +5.3% |
| Operating revenue | $24.26B | $23.03B | $21.73B | $19.08B | +5.3% |
| Cost of revenue | $13.84B | $13.62B | $12.80B | $11.05B | +1.6% |
| Gross profit | $10.41B | $9.40B | $8.93B | $8.03B | +10.7% |
| Total operating expense | $5.27B | $5.10B | $4.91B | $4.71B | +3.4% |
| Operating income | $5.14B | $4.31B | $4.01B | $3.32B | +19.5% |
| Net interest income | -$2.13B | -$1.91B | -$1.73B | -$1.45B | -11.1% |
| Pre-tax income | $3.29B | $2.67B | $2.70B | $2.40B | +23.4% |
| Tax provision | $523.00M | $207.00M | $374.00M | $349.00M | +152.7% |
| Net income | $2.77B | $2.46B | $2.33B | $2.17B | +12.5% |
| Net income to common | $2.77B | $2.46B | $2.33B | $2.17B | +12.5% |
| Basic EPS | 2.74 | 2.45 | 2.33 | 2.18 | +11.9% |
| Diluted EPS | 2.73 | 2.45 | 2.33 | 2.08 | +11.5% |
| EBIT | $5.42B | $4.58B | $4.43B | $3.85B | +18.3% |
| EBITDA | $9.06B | $8.18B | $7.94B | $7.17B | +10.8% |
| Basic shares | 1.01B | 1.01B | 999.00M | 994.00M | +0.6% |
| Diluted shares | 1.01B | 1.01B | 999.00M | 1.04B | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $626.00M | $357.00M | $445.00M | $407.00M | +75.4% |
| Cash & short-term investments | $626.00M | $357.00M | $445.00M | $407.00M | +75.4% |
| Accounts receivable | $3.30B | $2.74B | $2.34B | $2.22B | +20.4% |
| Inventory | $868.00M | $853.00M | $801.00M | $755.00M | +1.8% |
| Total current assets | $9.55B | $8.38B | $8.09B | $7.34B | +13.9% |
| Property, plant & equipment | $84.32B | $78.18B | $73.59B | $69.08B | +7.8% |
| Goodwill & intangibles | $6.63B | $6.63B | $6.63B | $6.63B | 0.0% |
| Total assets | $116.57B | $107.78B | $101.86B | $95.35B | +8.2% |
| Total current liabilities | $10.33B | $9.61B | $9.90B | $10.61B | +7.5% |
| Current debt | $2.28B | $3.31B | $3.93B | $4.39B | -31.3% |
| Long-term debt | $47.80B | $43.34B | $40.08B | $35.66B | +10.3% |
| Total debt | $50.08B | $46.65B | $44.01B | $40.05B | +7.4% |
| Total liabilities | $87.77B | $80.86B | $76.10B | $70.61B | +8.5% |
| Retained earnings | $7.58B | $6.43B | $5.49B | $4.60B | +17.9% |
| Shareholder equity | $28.80B | $26.92B | $25.75B | $24.74B | +7.0% |
| Working capital | -$785.00M | -$1.23B | -$1.81B | -$3.27B | +36.0% |
| Net tangible assets | $22.17B | $20.29B | $19.13B | $18.11B | +9.3% |
| Shares issued | 1.02B | 1.01B | 1.00B | 996.00M | +1.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $2.77B | $2.46B | $2.33B | $2.17B | +12.5% |
| Depreciation & amortisation | $3.05B | $2.92B | $2.79B | $2.77B | +4.4% |
| Change in working capital | -$1.52B | -$1.05B | -$852.00M | -$2.26B | -45.4% |
| Operating cash flow | $6.25B | $5.57B | $4.70B | $4.87B | +12.3% |
| Capital expenditure | -$8.53B | -$7.10B | -$7.41B | -$7.15B | -20.2% |
| Investing cash flow | -$8.53B | -$7.04B | -$7.38B | -$6.99B | -21.1% |
| Dividends paid | -$1.62B | -$1.52B | -$1.43B | -$1.33B | -6.1% |
| Financing cash flow | $2.53B | $1.31B | $2.68B | $1.59B | +93.2% |
| Free cash flow | -$2.27B | -$1.53B | -$2.71B | -$2.28B | -48.9% |
| End cash position | $1.20B | $939.00M | $1.10B | $1.09B | +27.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $5.97B | $7.24B | $5.41B | $6.71B | $5.43B | — | -17.6% |
| Operating revenue | $5.97B | $7.24B | $5.41B | $6.71B | $5.43B | — | -17.6% |
| Cost of revenue | $3.60B | $4.24B | $2.89B | $3.86B | $3.22B | — | -15.2% |
| Gross profit | $2.37B | $3.00B | $2.52B | $2.84B | $2.21B | — | -21.0% |
| Total operating expense | $1.39B | $1.40B | $1.34B | $1.34B | $1.28B | — | -0.3% |
| Operating income | $979.00M | $1.60B | $1.18B | $1.50B | $925.00M | — | -39.0% |
| Net interest income | -$574.00M | -$555.00M | -$549.00M | -$538.00M | -$531.00M | — | -3.4% |
| Pre-tax income | $495.00M | $1.12B | $721.00M | $1.03B | $461.00M | — | -55.8% |
| Tax provision | $99.00M | $200.00M | $127.00M | $155.00M | $70.00M | — | -50.5% |
| Net income | $396.00M | $919.00M | $594.00M | $875.00M | $391.00M | — | -56.9% |
| Net income to common | $396.00M | $919.00M | $594.00M | $875.00M | $391.00M | — | -56.9% |
| Basic EPS | 0.39 | 0.90 | 0.58 | 0.87 | 0.39 | — | -56.7% |
| Diluted EPS | 0.39 | 0.90 | 0.58 | — | 0.39 | 0.90 | -56.7% |
| EBIT | $1.07B | $1.67B | $1.27B | $1.57B | $992.00M | — | -36.1% |
| EBITDA | $2.04B | $2.63B | $2.19B | $2.48B | $1.89B | — | -22.4% |
| Basic shares | 1.02B | 1.02B | 1.02B | 1.01B | 1.01B | — | +0.1% |
| Diluted shares | 1.03B | 1.03B | 1.02B | 1.01B | 1.01B | — | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.81B | $713.00M | $626.00M | $1.53B | $724.00M | +154.3% |
| Cash & short-term investments | $1.81B | $713.00M | $626.00M | $1.53B | $724.00M | +154.3% |
| Accounts receivable | $3.06B | $3.11B | $3.30B | $2.90B | $3.06B | -1.8% |
| Inventory | $894.00M | $846.00M | $868.00M | $888.00M | $868.00M | +5.7% |
| Total current assets | $9.80B | $9.00B | $9.55B | $9.23B | $8.68B | +8.8% |
| Property, plant & equipment | $87.12B | $85.56B | $84.32B | $82.10B | $80.61B | +1.8% |
| Goodwill & intangibles | $6.63B | $6.63B | $6.63B | $6.63B | $6.63B | 0.0% |
| Total assets | $120.50B | $117.55B | $116.57B | $113.54B | $111.15B | +2.5% |
| Total current liabilities | $9.01B | $9.59B | $10.33B | $9.82B | $9.16B | -6.0% |
| Current debt | $1.97B | $2.99B | $2.28B | $3.25B | $2.93B | -34.1% |
| Long-term debt | $50.70B | $48.25B | $47.80B | $46.67B | $45.92B | +5.1% |
| Total debt | $52.67B | $51.24B | $50.08B | $49.92B | $48.84B | +2.8% |
| Total liabilities | $90.81B | $88.23B | $87.77B | $85.43B | $83.53B | +2.9% |
| Retained earnings | $8.03B | $8.06B | $7.58B | $7.39B | $6.92B | -0.4% |
| Shareholder equity | $29.70B | $29.32B | $28.80B | $28.11B | $27.62B | +1.3% |
| Working capital | $789.00M | -$586.00M | -$785.00M | -$596.00M | -$480.00M | +234.6% |
| Net tangible assets | $23.07B | $22.68B | $22.17B | $21.48B | $20.99B | +1.7% |
| Shares issued | 1.03B | 1.03B | 1.02B | 1.01B | 1.01B | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $396.00M | $919.00M | $594.00M | $874.00M | $392.00M | -56.9% |
| Depreciation & amortisation | $811.00M | $794.00M | $773.00M | $764.00M | $757.00M | +2.1% |
| Change in working capital | $235.00M | -$414.00M | -$596.00M | $81.00M | -$177.00M | +156.8% |
| Operating cash flow | $1.95B | $1.72B | $1.24B | $2.30B | $1.51B | +12.8% |
| Capital expenditure | -$2.20B | -$2.36B | -$2.43B | -$2.14B | -$2.01B | +6.7% |
| Investing cash flow | -$2.20B | -$2.36B | -$2.42B | -$2.14B | -$2.02B | +6.5% |
| Dividends paid | -$430.00M | -$430.00M | -$405.00M | -$404.00M | -$405.00M | 0.0% |
| Financing cash flow | $1.39B | $728.00M | $284.00M | $686.00M | $178.00M | +91.2% |
| Free cash flow | -$255.00M | -$634.00M | -$1.19B | $163.00M | -$502.00M | +59.8% |
| End cash position | $2.43B | $1.30B | $1.20B | $2.10B | $1.25B | +87.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $6.81B | +1.6% |
| Next quarter | — | — | $5.61B | +3.6% |
| Current year | — | — | $25.49B | +5.1% |
| Next year | — | — | $26.26B | +3.1% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.07%
Held by institutions95.39%
Institutions holding1.79K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
38.92
-0.17% from price
SMA 20
39.56
-1.77% from price
SMA 50
40.20
-3.34% from price
SMA 100
39.81
-2.41% from price
SMA 200
39.50
-1.63% from price
EMA 12
39.08
-0.57% from price
EMA 26
39.52
-1.69% from price
EMA 50
39.77
-2.31% from price
RSI (14)
44.4
Neutral
MACD (12,26,9)
-0.44
Hist -0.06
ATR (14)
0.42
1.09% of price
Realised vol 30D
28.4%
Annualised
Bollinger upper
41.58
20, 2σ
Bollinger lower
37.53
20, 2σ
50 / 200 cross
Golden
40.20 vs 39.50
Trend bias
Below 200
-1.63%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.07
Less volatile than market
Correlation to SPY
-0.04
Largely independent
Realised vol 30D
28.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-14.8%
Peak to trough
Max drawdown 5Y
-33.0%
Peak to trough
ATR 14
0.42
1.09% of price
Beta (reported)
0.40
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 21, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 13, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| Jul 16, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| May 29, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| May 15, 26 | TD Cowen | MAINTAINED | Hold | Hold |
| May 13, 26 | Keybanc | MAINTAINED | Underweight | Underweight |
| Apr 21, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Apr 21, 26 | Keybanc | MAINTAINED | Underweight | Underweight |
| Apr 21, 26 | Truist Securities | INITIATED | — | Hold |
| Apr 20, 26 | Jefferies | DOWNGRADE | Buy | Hold |
| Apr 20, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Apr 17, 26 | Barclays | DOWNGRADE | Overweight | Equal-Weight |
Dividends & splits
Forward rate$1.48 / yr
Forward yield3.80%
5-year avg yield3.50%
Payout ratio60.29%
Ex-dividend dateSep 4, 2026
Next pay date—
Last split—
Split date—
Headlines
TME Pharma provides update on its activities
GlobeNewswire · 9m ago
American Chemical Society Names Syngenta's Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals
Business Wire · 14m ago
Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
Business Wire · 14m ago
Board Update
GlobeNewswire · 14m ago
Aegon implements EUR 150 million increase in share buyback program
GlobeNewswire · 14m ago
TOMY's "TOMICA XROSS RESCUE" Diorama-based Short Animation Series to Begin Streaming Aug. 26, 2026
PR Newswire · 14m ago
Holding(s) in Company
GlobeNewswire · 14m ago
Summary of AB KN Energies webinar
GlobeNewswire · 14m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.